An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
Resource Type
CF Research News
Authors
References
J Cyst Fibros. 2019 Apr 30. pii: S1569-1993(19)30061-X. doi: 10.1016/j.jcf.2019.03.009.
Document
Link
Keywords
CFTR potentiator [3]
Ivacaftor [4]
KLIMB [5]
Pediatrics [6]
Safety [7]
Date
Tuesday, April 30, 2019
Featured resource article
Yes
Resource - Guideline Type
Other Guidelines [8]